PCOS Is Now PMOS: What Changed in May 2026
PCOS Is Now PMOS: What Changed in May 2026
12 min read · Updated May 18, 2026
Polycystic Ovary Syndrome no longer exists — at least, not by that name. On May 12, 2026, an international consortium of 56 medical and patient organizations published in The Lancet that PCOS is now officially Polyendocrine Metabolic Ovarian Syndrome (PMOS). The announcement came at the European Congress of Endocrinology in Prague, marking the largest coordinated effort to rename a medical condition in history.
If you or someone you know has PCOS — now PMOS — this isn't a label swap. It's a fundamental reframe of what the condition actually is. Here's what changed, why it matters, and what it means for your care going forward.
Key takeaways
- PCOS was officially renamed PMOS (Polyendocrine Metabolic Ovarian Syndrome) on May 12, 2026.
- The decision came from 56 organizations and over 22,000 patient and clinician responses across 14 years of work.
- Diagnosis and treatment haven't changed — only the name and the framing.
- A 3-year transition runs through 2028; both names are accepted clinically until then.
- PMOS affects an estimated 170 million women worldwide, and up to 70% remain undiagnosed.
Why the Old Name Was Wrong
"Polycystic Ovary Syndrome" implied two things that aren't true:
-
There are no abnormal cysts. The "polycystic" in PCOS referred to small follicles visible on ultrasound — but these are arrested follicles (eggs that didn't fully mature), not pathological cysts. Research led by Professor Helena Teede at Monash University confirmed that people with PMOS are no more likely to have true ovarian cysts than anyone else.
-
It's not just an ovary problem. PCOS was treated as a gynecological condition for decades. In reality, it involves disruptions across multiple hormonal pathways — including insulin signaling, androgen production, neuroendocrine regulation, and metabolic function. It affects weight, mental health, cardiovascular risk, skin, and fertility simultaneously.
The cost of the misleading name was measurable:
- Up to 70% of people with PMOS are undiagnosed (WHO estimate)
- In surveys, 86% of patients and 76% of health professionals agreed the name should change (The Lancet eClinicalMedicine, 2025)
- Diagnosis delays often span more than two years, with many women seeing three or more doctors before getting an answer
- Medical education and research funding skewed toward reproductive aspects, leaving metabolic and mental health dimensions under-resourced
"The name focuses on a criterion — polycystic ovarian morphology — which is neither necessary nor sufficient to diagnose the syndrome." — U.S. National Institutes of Health, 2012 recommendation
What Does PMOS Stand For?
Each word in Polyendocrine Metabolic Ovarian Syndrome was chosen through a global consensus process involving over 22,000 survey responses:
| Letter | Stands For | Why It Was Chosen |
|---|---|---|
| P | Polyendocrine | Acknowledges that multiple hormonal systems are involved — androgen, insulin, neuroendocrine, and ovarian hormone pathways — not just the ovaries |
| M | Metabolic | Highlights the strong connection to insulin resistance, type 2 diabetes risk, cardiovascular disease, and broader metabolic health |
| O | Ovarian | Retains the ovarian component (ovulation, follicle development, fertility) without overemphasizing it |
| S | Syndrome | Reflects that this is a cluster of related features, not a single disease with a single cause |
Why not "Reproductive"? The consortium specifically avoided the word "reproductive" because, as Teede explained: "In many cultures, the worth or value of a woman is linked to her fertility. Implying that women have a condition that might impact that — it can be very harmful." With appropriate diagnosis and treatment, most people with PMOS can achieve their desired family size.
Curious which pattern of PMOS you have? Our 5-minute assessment reads your symptoms and tells you. →
How Did This Happen? The 14-Year Journey
The push to rename PCOS didn't start in 2026. Here's the timeline:
- 1935 — Irving Stein and Michael Leventhal first describe the condition; it becomes known as "Stein-Leventhal Syndrome"
- 1990 — NIH conference establishes the first formal diagnostic criteria, using the name "Polycystic Ovary Syndrome"
- 2003 — Rotterdam criteria expand the diagnostic framework (2 of 3 criteria: hyperandrogenism, oligo-anovulation, polycystic ovarian morphology)
- 2012 — NIH convenes an expert panel that recommends a name change, calling PCOS a "confusing distraction"
- 2013–2023 — Multiple renaming efforts fail to gain international traction
- 2023 — International evidence-based PCOS guidelines (led by Teede) update diagnostic criteria and call for coordinated renaming
- 2024 — Perspective papers from researchers worldwide — including Ach Taieb et al. — propose specific alternatives like "Ovarian Dysmetabolic Syndrome" and build momentum
- 2026 (May 12) — 56 organizations across six continents publish the consensus in The Lancet and announce PMOS at the European Congress of Endocrinology in Prague
The process involved patients at every stage. As Lorna Berry, an Australian woman with PMOS who participated in the renaming, put it: "This is about my daughters, their daughters, and the countless women yet to be born. We deserve clarity, understanding, and equitable healthcare from the very beginning."
Mainstream coverage of the announcement from CNN and STAT News emphasized the same point: this rename is less about semantics and more about correcting decades of under-diagnosis and fragmented care.
Does This Change My Diagnosis or Treatment?
Your diagnosis criteria remain the same. An adult is diagnosed with PMOS if they meet at least two of three criteria (unchanged from the 2003 Rotterdam / 2023 International Guidelines):
- Irregular or absent periods (oligoanovulation) — fewer than 8 cycles per year, or cycle intervals outside 21–35 days
- Clinical or biochemical hyperandrogenism — excess hair growth, acne, scalp hair thinning, or elevated androgen levels on blood tests
- Polycystic-appearing ovaries on ultrasound or elevated AMH — high number of small antral follicles (this terminology will also be updated during the transition period)
For adolescents: Diagnosis requires both irregular cycles AND hyperandrogenism. Ultrasound alone is not sufficient.
Treatment approaches also remain the same, but the new name is expected to shift how comprehensively care is delivered:
Current First-Line Treatments
| Symptom/Goal | Treatment Approach |
|---|---|
| Insulin resistance | Lifestyle modification (diet + exercise) as first line; Metformin for BMI ≥25; GLP-1 receptor agonists (e.g., semaglutide) showing emerging benefit |
| Irregular periods | Combined oral contraceptives (COCs) for cycle regulation and endometrial protection |
| Excess hair/acne | COCs + antiandrogens for moderate-to-severe cases |
| Fertility | Letrozole as first-line ovulation induction; lifestyle optimization |
| Weight management | Structured diet + exercise; Metformin; GLP-1 agonists as adjunct |
| Mental health | Screening for anxiety and depression; psychological support; addressing hormonal contributors |
What the Name Change Will Shift
According to early commentary from the Endocrine Society and Contemporary OB/GYN, the practical effects are expected to include:
- More holistic screening at diagnosis — providers will assess metabolic, cardiovascular, and mental health markers alongside reproductive symptoms
- Better cross-specialty care — endocrinologists, cardiologists, and mental health professionals get involved, not just OB/GYNs
- Updated medical education — the new name signals to medical students and trainees that this is a systemic condition, not a niche gynecological diagnosis
- Research funding rebalance — metabolic and endocrine research receive more proportional attention
The Numbers Behind PMOS
Understanding the scale of this condition helps explain why the rename matters:
- 170 million+ women affected worldwide — roughly 1 in 8 women of reproductive age (Endocrine Society)
- Up to 70% are currently undiagnosed (WHO)
- Studies suggest a majority of women with PMOS who also have obesity experience compounded metabolic effects
- Research estimates roughly 45% experience some level of glucose intolerance (prediabetes or type 2 diabetes)
- ~15–45% show adrenal hyperandrogenism — meaning excess androgens aren't even coming from the ovaries
- Estimated 2–4× higher risk of type 2 diabetes compared to the general population
- Increased risk of cardiovascular disease, endometrial cancer, sleep apnea, and depression
- $8 billion+ estimated annual healthcare cost for PMOS in the United States alone (AJMC)
These numbers make it clear: calling this an "ovary syndrome" was always reductive. The metabolic and endocrine dimensions are not secondary — they're central.
What Happens During the 3-Year Transition?
The rename doesn't flip a switch overnight. Here's the rollout plan:
- 2026–2028 — Three-year transition period with a global education and awareness campaign targeting patients, providers, governments, and researchers
- 2028 — Full integration into the updated International PMOS Guidelines (the successor to the 2023 International PCOS Guidelines)
- Ongoing — Medical terminology updates, including replacing "polycystic ovarian morphology" with more accurate language for ultrasound findings
- Resources — The AskPCOS app (developed by Monash University) will be renamed AskPMOS and updated with new educational materials
During the transition, both PCOS and PMOS will be used interchangeably in clinical settings. Your existing diagnosis is valid — no one needs to be re-diagnosed.
Frequently Asked Questions
Is PMOS a different condition from PCOS?
No. PMOS is the same condition as PCOS with a new, more accurate name. Your diagnosis, treatment plan, and medical history remain unchanged.
Do I need to get re-diagnosed?
No. If you have a PCOS diagnosis, it automatically applies under the PMOS name. No new tests or appointments are needed for the name change itself.
Why wasn't "PCOS" kept as the acronym for easier adoption?
During the global consensus process, respondents prioritized scientific accuracy over preserving the old acronym. The new name needed to correctly describe the condition's features — polyendocrine, metabolic, and ovarian.
Why was "PMOS" chosen over "Ovarian Dysmetabolic Syndrome" and other proposed alternatives?
Earlier 2024 perspective papers — including Taieb et al. — proposed names like "Ovarian Dysmetabolic Syndrome." The consortium ultimately chose PMOS because patients and clinicians in the consensus survey preferred a name that explicitly signals polyendocrine involvement (multiple hormonal systems), not just metabolic dysfunction.
Does the name change affect insurance coverage or prescriptions?
No immediate changes are expected. ICD codes and insurance classifications will be updated during the three-year transition period to reflect the new terminology.
When will my doctor start using "PMOS"?
The three-year transition period runs from 2026 to 2028. Many providers will begin using both names immediately, with full adoption expected by the 2028 guideline update.
Where can I find reliable information about PMOS?
- AskPCOS / AskPMOS App by Monash University
- International PCOS Guidelines (to be updated as PMOS Guidelines)
- WHO Fact Sheet
- The Lancet Consensus Paper
Find Out Where You Stand
If you've been told you have PCOS — or you suspect you do — the PMOS rename doesn't change what you do next. It just clarifies what's actually going on.
Oestra's 5-minute assessment reads your symptoms across cycle, skin, weight, mood, and fertility, and tells you which of the four PMOS patterns you most likely fit. From there, you get a plan that targets your pattern — not the average patient's.
This article is for informational purposes only and does not constitute medical advice. If you suspect you have PMOS (formerly PCOS), consult a qualified healthcare professional for diagnosis and treatment.
References
- Teede, H.J., et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. https://doi.org/10.1016/S0140-6736(26)00717-8
- Ach Taieb, et al. (2024). Rethinking the Terminology: A Perspective on Renaming Polycystic Ovary Syndrome for an Enhanced Pathophysiological Understanding. Clinical Medicine Insights: Endocrinology and Diabetes, 17, 1–11. https://doi.org/10.1177/11795514241296777
- Teede, H.J., et al. (2023). International evidence-based guideline for the assessment and management of PCOS. J Clin Endocrinol Metab, 108, 2447–2469.
- Bozdag, G., et al. (2016). The prevalence and the phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction, 31(12), 2841–2855.
- World Health Organization. Polycystic ovary syndrome. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome
- NIH Evidence-based Methodology Workshop on PCOS (2012). Final Report. https://prevention.nih.gov/sites/g/files/mnhszr241/files/2018-06/FinalReport.pdf
Curious which pattern of PCOS (PMOS) you have?
Our 5-minute assessment reads your symptoms and tells you the pattern.